Overview

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the first-line treatment of CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

Capecitabine
Injections
Oxaliplatin